



Prior Authorization Request

LUCENTIS, BYOOVIZ, RANOPTO (ranibizumab)

Instructions

Please complete Part A and have your physician complete Part B. Completion and submission is not a guarantee of approval. Any fees related to the completion of this form are the responsibility of the plan member. Drugs in the Prior Authorization Program may be eligible for reimbursement if the patient does not qualify for coverage under a primary plan or a government program. Drugs used for indications not approved by Health Canada may be denied. For Quebec plan members, RAMQ exception drug criteria may apply. The decision for approval versus denial is based on pre-defined clinical criteria, primarily based on Health Canada approved indication(s) and on supporting evidence-based clinical protocols. The plan member will be notified whether their request has been approved or denied. Please note that you have the right to appeal the decision made by Express Scripts Canada.

Part A – Patient

Patient information

First Name:		Last Name:	
Insurance Carrier Name/Number:			
Group Number:		Client ID:	
Date of Birth (YYYY/MM/DD):		Relationship: <input type="checkbox"/> Employee <input type="checkbox"/> Spouse <input type="checkbox"/> Dependent	
Language: <input type="checkbox"/> English <input type="checkbox"/> French		Gender: <input type="checkbox"/> Male <input type="checkbox"/> Female	
Address:			
City:	Province:	Postal Code:	
Email address:			
Telephone (home):	Telephone (cell):	Telephone (work):	

Coordination of benefits

Patient Assistance Program	Is the patient enrolled in any patient assistance program? <input type="checkbox"/> Yes <input type="checkbox"/> No Contact Name: _____ Fax: _____
Provincial Coverage	Has the patient applied for reimbursement under a provincial plan? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> N/A What is the coverage decision of the drug? <input type="checkbox"/> Approved <input type="checkbox"/> Denied <i>*Attach decision letter*</i>
Primary Coverage	Has the patient applied for reimbursement under a primary plan? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> N/A What is the coverage decision of the drug? <input type="checkbox"/> Approved <input type="checkbox"/> Denied <i>*Attach decision letter*</i>

Authorization

On behalf of myself and my eligible dependents, I authorize my group benefit provider, and its agents, to exchange the personal information contained on this form. I give my consent on the understanding that the information will be used solely for purposes of administration and management of my group benefit plan. This consent shall continue so long as my dependents and I are covered by, or are claiming benefits under the present group contract, or any modification, renewal, or reinstatement thereof.

Plan Member Signature

Date



Prior Authorization Request
LUCENTIS, BYOOVIZ, RANOPTO (ranibizumab)

Part B – Prescriber

Please see instructions on page 1 and complete all sections below. Incomplete forms may result in automatic denial. Please do not provide genetic test information or results.

SECTION 1 – DRUG REQUESTED

Form with checkboxes for LUCENTIS, BYOOVIZ, RANOPTO, New request, Renewal request*, and site of drug administration (Home, Physician's office, Hospital outpatient, Hospital inpatient).

* Please submit proof of prior coverage if available

SECTION 2 – ELIGIBILITY CRITERIA

1. Please indicate if the patient satisfies the below criteria:
Neovascular (Wet) Age-Related Macular Degeneration
Diabetic Macular Edema
Macular Edema Secondary to Retinal Vein Occlusion
Choroidal Neovascularization
Retinopathy of Prematurity



Prior Authorization Request
LUCENTIS, BYOOVIZ, RANOPTO (ranibizumab)

OR

None of the above criteria applies.

Relevant additional information:

Empty rectangular box for additional information.

2. Please list previously tried therapies

Table with 6 columns: Drug, Dosage and administration, Duration of therapy (From, To), Reason for cessation (Inadequate response, Allergy/Intolerance). Contains 6 empty rows for data entry.

3. Additional criteria for LUCENTIS requests

The patient is intolerant to, or had a confirmed adverse event with a biosimilar (Please indicate in the chart above)

SECTION 3 - PRESCRIBER INFORMATION

Form for prescriber information including fields for Physician's Name, Address, Tel, Fax, License No., Specialty, Physician Signature, and Date.

Please fax or mail the completed form to Express Scripts Canada®

Fax: Express Scripts Canada Clinical Services 1 (855) 712-6329

Mail: Express Scripts Canada Clinical Services 6985 Financial Drive, Suite 300 Mississauga, ON, L5N 0G3